Similar articles for PMID: 19442034

Year	Number of Results
1974	1
1999	4
2000	1
2001	3
2003	3
2004	3
2005	3
2006	3
2007	12
2008	21
2009	49
2015	3
2016	3
2017	2
2018	1
2019	1
2020	2
2021	2
2022	2
2024	0

1

Antiviral drug disposition and natural health products: risk of therapeutic alteration and resistance.

MacDonald L, Murty M, Foster BC. MacDonald L, et al. Expert Opin Drug Metab Toxicol. 2009 Jun;5(6):563-78. doi: 10.1517/17425250902942302. Expert Opin Drug Metab Toxicol. 2009. PMID: 19442034 Review.

2

Natural health product-HIV drug interactions: a systematic review.

Mills E, Montori V, Perri D, Phillips E, Koren G. Mills E, et al. Int J STD AIDS. 2005 Mar;16(3):181-6. doi: 10.1258/0956462053420103. Int J STD AIDS. 2005. PMID: 15829016

3

Raltegravir: new Drug. Alternative to enfuvirtide/darunavir in multidrug-resistant HIV.

[No authors listed] [No authors listed] Prescrire Int. 2008 Aug;17(96):135-7. Prescrire Int. 2008. PMID: 19480091

4

[Immunosuppressive drugs and highly active antiretroviral therapy: pharmacokinetic interactions].

Moretto J, Bessard G, Stanke-Labesque F. Moretto J, et al. Therapie. 2007 Jul-Aug;62(4):327-35. doi: 10.2515/therapie:2007060. Epub 2007 Nov 6. Therapie. 2007. PMID: 17983558 Review. French.

5

High frequency of antiretroviral drug resistance among HIV-infected adults receiving first-line highly active antiretroviral therapy in N'Djamena, Chad.

Koyalta D, Charpentier C, Beassamda J, Rey E, Si-Mohamed A, Djemadji-Oudjeil N, Bélec L. Koyalta D, et al. Clin Infect Dis. 2009 Jul 1;49(1):155-9. doi: 10.1086/599611. Clin Infect Dis. 2009. PMID: 19480574

6

HIV pharmacogenomics: closer to personalized therapy?

Payne DA, Bryant BJ; AACC Pharmacogenomic Committee. Payne DA, et al. Am J Pharmacogenomics. 2004;4(3):141-50. Am J Pharmacogenomics. 2004. PMID: 15174895 Review.

7

Fosamprenavir/ritonavir in advanced HIV disease (TRIAD): a randomized study of high-dose, dual-boosted or standard dose fosamprenavir/ritonavir in HIV-1-infected patients with antiretroviral resistance.

Molina JM, Ait-Khaled M, Rinaldi R, Penco G, Baril JG, Cauda R, Soriano V, Pialoux G, Wire MB, Lou Y, Givens N, Craig C, Nichols WG, Barbosa I, Yeo J; TRIAD Study Group. Molina JM, et al. J Antimicrob Chemother. 2009 Aug;64(2):398-410. doi: 10.1093/jac/dkp198. Epub 2009 Jun 10. J Antimicrob Chemother. 2009. PMID: 19515730 Clinical Trial.

8

Drug resistant mutations detected by genotypic drug resistance testing in patients failing therapy in clade C HIV-1 infected individuals from India.

Kandathil AJ, Kannangai R, Verghese VP, Pulimood SA, Rupali P, Sridharan G, Grant P, Pillay D, Abraham OC. Kandathil AJ, et al. Indian J Med Microbiol. 2009 Jul-Sep;27(3):231-6. doi: 10.4103/0255-0857.53205. Indian J Med Microbiol. 2009. PMID: 19584504 Free article.

9

[Antiretroviral therapy of HIV infection. German-Austrian guidelines (position in September 2008)].

Gemeinsame Erklärung der Deutschen AIDS-Gesellschaft (DAIG); Osterreichischen AIDS-Gesellschaft (OAG). Gemeinsame Erklärung der Deutschen AIDS-Gesellschaft (DAIG), et al. Dtsch Med Wochenschr. 2009 Jan;134 Suppl 1:S4-15. doi: 10.1055/s-0028-1123965. Epub 2009 Jan 26. Dtsch Med Wochenschr. 2009. PMID: 19172554 Review. German. No abstract available.

10

Review. Drug resistance of human immunodeficiency virus and overcoming it by natural products.

Hupfeld J, Efferth T. Hupfeld J, et al. In Vivo. 2009 Jan-Feb;23(1):1-6. In Vivo. 2009. PMID: 19368117 Free article. Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Results by year

Text availability

Article attribute

Article type

Publication date

116 results

Results by year